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Key	Points	Summary	62 
• Voltage-gated	sodium	channels	play	a	fundamental	role	in	determining	neuronal	63 excitability	64 
• Specifically,	voltage-gated	sodium	channel	subtype	NaV1.7	is	required	for	sensing	65 acute	and	inflammatory	somatic	pain	in	mice	and	humans	but	its	significance	in	66 pain	originating	from	the	viscera	is	unknown.	67 
• Using	comparative	behavioural	models	evoking	somatic	and	visceral	pain	68 pathways,	we	identify	the	requirement	for	NaV1.7	in	regulating	somatic	(noxious	69 heat	pain	threshold)	but	not	in	visceral	pain	signalling.		70 
• These	results	enable	us	to	better	understand	the	mechanisms	underlying	the	71 transduction	of	noxious	stimuli	from	the	viscera,	suggest	that	the	investigation	of	72 pain	pathways	should	be	undertaken	in	a	modality-specific	manner	and	help	to	73 direct	drug	discovery	efforts	towards	novel	visceral	analgesics.	74 
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Abstract	75 Voltage-gated	sodium	channel	NaV1.7	is	required	for	acute	and	inflammatory	pain	in	76 mice	and	humans	but	its	significance	for	visceral	pain	is	unknown.	Here	we	examine	the	77 role	of	NaV1.7	in	visceral	pain	processing	and	the	development	of	referred	hyperalgesia	78 using	a	conditional	nociceptor-specific	NaV1.7	knockout	mouse	(NaV1.7Nav1.8)	and	79 selective	small-molecule	NaV1.7	antagonist	PF-5198007.	NaV1.7Nav1.8	mice	showed	80 normal	nociceptive	behaviors	to	intracolonic	application	of	either	capsaicin	or	mustard	81 oil,	stimuli	known	to	evoke	sustained	nociceptor	activity	and	sensitization	following	82 tissue	damage,	respectively.	Normal	responses	following	induction	of	cystitis	by	83 cyclophosphamide	were	also	observed	in	both	NaV1.7Nav1.8	and	littermate	controls.	Loss,	84 or	blockade,	of	NaV1.7	did	not	affect	afferent	responses	to	noxious	mechanical	and	85 chemical	stimuli	in	nerve-gut	preparations	in	mouse,	or	following	antagonism	of	NaV1.7	86 in	resected	human	appendix	stimulated	by	noxious	distending	pressures.	However,	87 expression	analysis	of	voltage-gated	sodium	channel	α	subunits	revealed	NaV1.7	mRNA	88 transcripts	in	nearly	all	retrogradely-labelled	colonic	neurons	suggesting	redundancy	in	89 function.	By	contrast,	using	comparative	somatic	behavioral	models	we	identify	that	90 genetic	deletion	of	NaV1.7	(in	NaV1.8-expressing	neurons)	regulates	noxious	heat	pain	91 threshold	and	that	this	can	be	recapitulated	by	the	selective	NaV1.7	antagonist	PF-92 5198007.	Our	data	demonstrates	that	NaV1.7	(in	NaV1.8-expressing	neurons)	93 contributes	to	defined	pain	pathways	in	a	modality-dependent	manner,	modulating	94 somatic	noxious	heat	pain	but	is	not	required	for	visceral	pain	processing,	and	95 advocates	that	pharmacological	block	of	NaV1.7	alone	in	the	viscera	may	be	insufficient	96 in	targeting	chronic	visceral	pain.	97 	98 
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Abbreviations	99 BSA	 Bovine	serum	albumin	CIP	 Congenital	insensitivity	to	pain	CT	 Quantification	cycles	DRG	 Dorsal	root	ganglia	FB	 Fast	Blue	GAPDH	 Glyceraldehyde-3-phosphate	dehydrogenase		IC/BPS	 Interstitial	cystitis/bladder	pain	syndrome	LS	 Lumbosacral	NaV	 Voltage-gated	sodium	channel	PEPD	 Paroxysmal	extreme	pain	disorder	PO	 Per	os	QST	 Quantitative	standardized	testing	TL	 Thoracolumbar	TRPV1	 Transient	receptor	potential	cation	channel	V1	TTX-R	 Tetrodotoxin-resistant	TTX-S	 Tetrodotoxin-sensitive		100 
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Introduction		101 Chronic	pain	originating	from	internal	organs	affects	significant	proportions	of	the	102 population	with	analgesics	restricted	by	dose-limiting	side-effects.	Persistent	pain	and	103 visceral	hypersensitivity	manifests	as	reduced	thresholds	for	mechanical	distension	of	104 visceral	organs	and	are	strongly	associated	with	inflammation.	The	targeting	of	105 peripheral	sensory	input,	either	by	peripheral	nerve	block	(Cherry	et	al.,	1985;	Brown,	106 1989;	Eisenberg	et	al.,	1995)	or	local	anaesthetics	(Verne	et	al.,	2003;	Verne	et	al.,	2005)	107 has	proven	effective	in	treating	visceral	pain.	However,	our	understanding	of	key	108 sensory	afferent	transduction	mechanisms	responsible	for	visceral	nociception	is	109 limited.	Here,	we	investigate	voltage-gated	sodium	channel	NaV1.7	in	both	visceral	and	110 somatic	pain	behaviors	and	show	that	peripheral	pain	pathways	of	the	viscera	are	111 functionally	distinct	from	classical	nociceptors,	providing	evidence	supporting	112 functional	diversity	of	nociception	and	confirmation	that	novel	analgesic	development	113 must	be	applied	in	a	mechanism-specific	manner.	114 Rare	human	genetic	conditions	link	NaV1.7	to	pain	perception,	with	loss-of-function	115 mutations	causing	congenital	insensitivity	to	pain	(CIP)	(Cox	et	al.,	2006;	Goldberg	et	al.,	116 2007).	Recapitulation	of	the	human	painless	phenotype	using	knockout	mice	genetically	117 engineered	to	globally	lack	NaV1.7	results	in	complete	loss	of	responses	to	acute,	118 inflammatory	and	neuropathic	pain	(Gingras	et	al.,	2014).	Using	tissue-specific	NaV1.7	119 knockout	mice	(including	nociceptor-specific	NaV1.7Nav1.8	mice	(Nassar	et	al.,	2004),	120 pan-sensory	neuron	NaV1.7Advill	mice	(Minett	et	al.,	2012)	and	pan-sensory	and	121 sympathetic	neuron	NaV1.7Wnt1	mice	(Minett	et	al.,	2012))	modality-specific	pain	122 pathways	associated	with	acute	heat	and	mechanical	detection,	hyperalgesia	and	123 allodynia	have	been	linked	with	differing	NaV	repertoires.		124 
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Intriguingly,	CIP	patients	feel	no	visceral	pain	with	reports	of	both	painless	childbirth	125 and	rupture	of	appendix	(Melzack	&	Wall,	1988;	Zimmermann	et	al.,	1988;	Wheeler,	126 2015),	suggesting	that	NaV1.7	may	be	required	for	visceral	nociception.	Rectal	pain	is	a	127 symptom	of	paroxysmal	extreme	pain	disorder	(PEPD),	another	condition	associated	128 with	rare	NaV1.7	mutations	(Fertleman	et	al.,	2006),	with	defecation	capable	of	129 triggering	pain	attacks	implicating	a	link	to	anorectal	distension.	In	patients	with	130 interstitial	cystitis/bladder	pain	syndrome	(IC/BPS),	pain	perception	associates	with	131 NaV1.7	mutations	(Reeder	et	al.,	2013).	Like	other	chronic	pain	conditions,	a	hallmark	of	132 IC/BPS	is	ongoing	pain	in	the	absence	of	obvious	pathophysiology	(Dimitrakov	&	133 Guthrie,	2009).	Therefore	NaV1.7	could	be	involved	in	maintaining	spontaneous	pain,	134 such	as	peripheral	or	central	sensitization,	in	addition	to	evoked	pain	attributed	to	135 mechanical	stimulation.	Surprisingly,	whilst	broad-spectrum	sodium	channel	blockers	136 are	effective	in	treating	chronic	visceral	pain,	selective	NaV1.7	antagonists	(ProTx-II)	137 and	monoclonal	blocking	antibodies	targeting	NaV1.7	have	been	unable	to	fully	138 recapitulate	loss	of	NaV1.7	mutant	phenotypes	to	other	chronic	pain	models	139 (Schmalhofer	et	al.,	2008;	Lee	et	al.,	2014).	Indeed,	selective	antagonism	of	NaV1.7	with	140 ProTx-II	also	failed	to	block	afferent	responses	to	stretch	of	the	colorectum	(Feng	et	al.,	141 2015),	suggesting	the	contribution	of	NaV1.7	to	visceral	pain	processing	is	still	unclear.		142 In	light	of	recent	findings	that	NaV1.7	is	essential	for	some	(acute	heat	and	mechanical	143 pain,	inflammatory	hyperalgesia	and	neuropathic	allodynia),	but	not	all	(acute	cold	pain,	144 cancer-induced	bone	pain	and	oxaliplatin-evoked	allodynia)	pain	modalities,	we	145 investigated	visceral	pain	and	referred	hyperalgesia	using	a	conditional	nociceptor-146 specific	NaV1.7	knockout	mouse	(NaV1.7Nav1.8)	and	selective	NaV1.7	antagonist	PF-147 5198007.	Thus,	using	comparative	behavioral	models	evoking	somatic	and	visceral	pain	148 pathways	we	identify	specific	mechanisms	regulating	noxious	heat	pain	threshold	and	149 
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show	that	NaV1.7	in	NaV1.8-expressing	neurons	is	not	required	for	visceral	pain	150 signalling.		151 
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Materials	and	Methods	152 Experiments	were	performed	in	adult	mice	weighing	20	–	35	g.	Conditional	nociceptor-153 specific	NaV1.7	knockout	mice	(NaV1.7Nav1.8)	and	their	littermate	controls	were	154 generated	as	described	previously	(Nassar	et	al.,	2004).	Observers	performing	155 behavioral	and	ex	vivo	electrophysiological	experiments	were	blind	to	the	genotypes	of	156 the	animals.	Animals	were	acclimatized	for	at	least	one	week	before	behavioral	testing	157 in	temperature	and	light-controlled	(12hr	light/dark	cycle)	rooms.	All	experiments	158 were	performed	in	accordance	with	the	UK	Animals	(Scientific	Procedures)	Act	of	1986	or	159 with	the	EU	Directive	2010/63/EU	for	animal	experimentation,	with	approval	of	the	160 University	of	Granada	Research	Ethics	Committee	(Granada,	Spain).	Human	tissues	were	161 collected	and	utilised	with	approval	of	the	East	London	and	The	City	HA	Local	Research	162 Ethics	Committee	(London,	UK;	NREC	10/H0703/71)	in	accordance	with	the	Declaration	163 of	Helsinki	and	following	full	written	informed	consent.		164 
Behavioral	experiments		165 Experiments	were	performed	on	both	male	and	female	knockout	and	wild-type	166 littermate	control	mice.	Visceral	pain	and	referred	hyperalgesia	was	assessed	using	167 previously	described	methods,	with	small	modifications	(Olivar	&	Laird,	1999;	Laird	et	168 
al.,	2001;	Gonzalez-Cano	et	al.,	2013).	Briefly,	mice	were	acclimatized	for	40	minutes	to	169 test	chambers	(consisting	of	a	transparent	box	on	an	elevated	wire	mesh	floor)	after	170 which	50μl	of	capsaicin	(0.1	or	1%),	mustard	oil	(0.01	or	0.1%)	or	vehicle	was	instilled	171 intrarectally	via	a	thin	cannula	inserted	into	the	anus	and	the	animal	returned	to	the	172 chamber.	The	number	of	spontaneous	pain	behaviors	(including	licking	of	abdomen,	173 stretching	of	abdomen	and	abdominal	retractions)	were	recorded	for	the	subsequent	20	174 minutes.	In	a	separate	set	of	experiments,	visceral	pain	behaviors	caused	by	175 cyclophosphamide-induced	cystitis	were	examined	following	a	previously	described	176 
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protocol	(Olivar	&	Laird,	1999).	Again	after	a	40	min	habituation,	animals	were	177 removed	from	the	test	chamber	and	cyclophosphamide	(100	or	200mg/kg)	or	vehicle	178 injected	intraperitoneally.	The	animals	were	returned	to	the	chamber	and	pain	179 behaviors	recorded	according	to	the	following	scale:	0	=	normal,	1	=	piloerection,	2	=	180 strong	piloerection,	3	=	labored	breathing,	4	=	licking	of	the	abdomen	and	5	=	stretching	181 and	contraction	of	the	abdomen.	If	more	than	one	of	these	behaviors	was	noted	during	a	182 single	observation	period,	then	only	the	type	and	not	quantity	of	each	different	pain	183 behavior	was	scored	(i.e.	if	two	stretching	and	contractions	(5	points)	and	one	184 abdominal	licking	(4	points)	was	observed,	then	a	score	of	9	was	assigned).		185 After	the	evaluation	of	spontaneous	pain	behaviors	(primary	behavioral	endpoint),	the	186 presence	of	referred	hyperalgesia	was	determined	by	measuring	the	withdrawal	187 response	to	a	punctate	mechanical	stimulation	(von	Frey	hair	filaments	0.02	–	2	g	(0.19-188 19.6	mN),	Touch-Test	Sensory	Evaluators,	North	Coast	Medical	Inc.,	USA)	of	the	189 abdomen	using	the	up-down	paradigm	20	minutes	after	algogen	administration	190 (Chaplan	et	al.,	1994).	Avoiding	the	perianal	and	external	genitalia,	the	mid-range	0.4	g	191 von	Frey	hair	filament	was	applied	(three	times	for	2-3	sec	at	5	sec	intervals)	to	the	192 lower	and	mid	abdomen.	If	a	positive	response	(consisting	of	immediate	193 licking/scratching	of	the	application	site,	sharp	retraction	of	the	abdomen	or	jumping)	194 was	observed,	then	probing	was	repeated	in	consecutive	tests	with	a	weaker	von	Frey	195 filament.	By	contrast	if	there	was	no	response	to	probing	then	a	stronger	von	Frey	196 filament	was	used.	Once	the	withdrawal	threshold	(secondary	behavioral	endpoint)	was	197 ascertained,	mice	were	humanely	killed	by	concussion	of	the	brain	and	cervical	198 dislocation	of	the	neck.		199 
Electrophysiological	recordings	of	visceral	afferent	activity	200 
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Nerves	innervating	murine	and	human	gastrointestinal	tissues	were	isolated	and	201 electrophysiological	activity	recorded	using	previously	described	methods	(Peiris	et	al.,	202 2011;	Hockley	et	al.,	2014).	Mice	were	humanely	killed	by	concussion	of	the	brain	and	203 cervical	dislocation	of	the	neck.	The	distal	colon	with	associated	lumbar	splanchnic	204 nerves	was	removed	and	transferred	to	a	recording	chamber	superfused	(7	ml/min;	32-205 34	oC)	with	carbogenated	Krebs	buffer	(in	mM:	124	NaCl,	4.8	KCl,	1.3	NaH2PO4,	2.5	206 CaCl2,	1.2	MgSO4.7H2O,	11.1	glucose,	and	25	NaHCO3)	supplemented	with	nifedipine	(10	207 µM),	atropine	(10μM)	and	indomethacin	(3	µM).	The	same	supplemented	Krebs	buffer	208 was	used	to	luminally	perfuse	(100	µl/min)	the	colon	after	cannulation.		209 To	translate	murine	experimental	recordings	into	human	tissue,	we	recorded	extrinsic	210 nerve	activity	from	resected	human	appendices.	We	have	previously	shown	that	the	211 appendix	represents	a	valid	human	ex	vivo	model	of	visceral	afferent	activity	amenable	212 to	the	testing	of	mechanical	and	chemical	stimuli	(Peiris	et	al.,	2011).	Specifically,	the	213 extrinsic	nerves	of	the	appendix	are	a	branch	of	those	innervating	the	right	colon	along	214 the	ileocolic	artery	and	represent	a	readily	available	tissue	in	normal	non-inflamed	(e.g.	215 from	colon	cancer	resections)	states.	Resected	appendices	were	obtained	from	5	216 patients	undergoing	elective	surgery	at	Barts	Health	NHS	Trust,	London	after	full	217 written	consent	was	attained.	Appendices	were	removed	from	patients	undergoing	218 right	hemicolectomies	as	part	of	their	normal	surgical	treatment	for	bowel	cancer	or	219 slow	transit	constipation	(see	Table	1	for	details)	with	the	permission	of	the	220 histopathologist	and	were	returned	to	the	morbid	anatomy	department	after	221 completion	of	the	studies.	Once	removed,	appendix	specimens	were	immediately	placed	222 in	cold	Krebs	buffer	and	handled	in	a	comparable	manner	to	mouse	distal	colon	tissues.	223 Removal	of	the	tip	and	cannulation	enabled	intraluminal	perfusion,	in	addition	to	224 superfusion	with	Krebs	buffer	(7	mL/min;	32-34	oC)	supplemented	with	10	µM	225 
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nifedipine	and	10	µM	atropine.	Under	a	dissection	microscope,	mesenteric	226 neurovascular	bundles	were	blunt	dissected	and	associated	nerves	identified	and	227 cleared	of	connective	tissue.	Using	borosilicate	glass	suction	electrodes,	multi-unit	228 activity	from	whole	lumbar	splanchnic	nerves	(rostral	to	the	inferior	mesenteric	229 ganglia)	of	mouse,	or	from	mesenteric	nerves	of	human	bowel	tissues,	was	recorded.	230 Signals	were	amplified	and	band	pass	filtered	(gain	5	K;	100-1300	Hz;	Neurolog,	231 Digitimer	Ltd,	UK)	and	digitized	at	20	kHz	(micro1401;	Cambridge	Electronic	Design,	232 UK)	before	display	on	a	PC	using	Spike	2	software.	The	signal	was	digitally	filtered	for	233 50	Hz	noise	(Humbug,	Quest	Scientific,	Canada)	and	a	threshold	of	twice	the	background	234 noise	(typically	100	µV)	was	used	to	determine	action	potential	firing	counts.		235 
Electrophysiological	protocols	236 Following	a	stabilizing	period	of	30	minutes,	noxious	intraluminal	distending	pressures	237 were	applied	by	blocking	the	luminal	perfusion	out-flow	of	the	cannulated	mouse	distal	238 colon	or	resected	human	appendix.	The	noxious	pressures	reached	evoke	pain	239 behaviors	in	vivo	and	are	above	threshold	for	all	known	visceral	afferent	240 mechanoreceptors	(Ness	&	Gebhart,	1988;	Hughes	et	al.,	2009).	In	murine	experiments,	241 a	combined	sequential	protocol	was	used	to	initially	assess	multiple	aspects	of	visceral	242 afferent	mechanosensitivity	and	chemosensitivity.	Specifically,	a	set	of	6	rapid	phasic	243 distensions	(0-80	mm	Hg,	60	s	at	9	min	intervals)	followed	by	slow	ramp	distension	(0-244 145	mmHg,	~5-6	min)	were	implemented	prior	to	bath	superfusion	of	separate	20	ml	245 volumes	of	1	μM	bradykinin	and	1mM	ATP	at	40	min	intervals.	In	separate	experiments,	246 the	effect	of	pharmacological	inhibition	of	NaV1.7	on	visceral	afferent	sensitivity	to	247 mechanical	distension	or	noxious	stimulation	by	capsaicin,	mustard	oil	or	bradykinin	248 was	tested.	A	set	of	9	rapid	phasic	distensions	(0-80	mm	Hg,	60	s	at	9	min	intervals)	249 followed	by	a	30	min	stabilization	period	and	bath	superfusion	of	1	μM	bradykinin	in	a	250 
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20	ml	volume	were	performed.	Prior	to	the	7th	phasic	distension,	bath	superfusion	of	251 the	selective	NaV1.7	antagonist	PF-5198007	(100	nM;	500	mL;	(Alexandrou	et	al.,	252 2016))	or	vehicle	(0.1	%	DMSO)	was	initiated	and	maintained	for	the	duration	of	the	253 remaining	three	distensions	and	bradykinin	application.	In	some	experiments,	after	a	254 wash-out	period,	repeat	phasic	distensions	were	performed	during	which	250	ml	255 tetrodotoxin	(TTX;	100	nM)	was	superfused.	In	separate	experiments,	a	ramp	256 distension	(0-145mmHg)	was	performed	followed	by	bath	superfusion	of	capsaicin	257 (500nM)	and	mustard	oil	(250	μM)	at	1	hour	interval.	Five	minutes	prior	to	application	258 of	capsaicin,	either	100nM	PF-5198007	or	vehicle	(0.1%	DMSO)	was	applied	for	the	259 duration	of	the	subsequent	stimulations.	Human	appendix	specimens	were	stimulated	260 in	a	comparable	manner	by	repeat	ramp	distension	(0-60	mm	Hg,	~30	s	at	9	min	261 intervals).	Baseline	responses	were	established	for	three	distensions	prior	to	the	262 superfusion	of	PF-5198007	(100	nM	or	1	μM)	for	50	min	during	subsequent	263 distensions.		264 
Retrograde	labelling	of	gut-specific	sensory	neurons	and	single-cell	qRT-PCR	265 
Distal	colon-specific	sensory	neurons	were	retrogradely	labelled,	picked	and	the	266 expression	of	mRNA	transcripts	of	interest	determined	by	qRT-PCR.	A	mid-line	1.5cm	267 laparotomy	was	performed	on	male	mice	after	induction	of	anaesthesia	with	1.5%	268 isoflurane.	Multiple	injections	of	Fast	Blue	(FB:	0.2	μl	per	site,	2%	in	saline,	Polysciences	269 Gmbh,	Germany)	were	made	using	a	fine	pulled-glass	needle	and	microinfusion	pump	270 (0.4	μl/min)	into	the	wall	of	the	distal	colon.	Prior	to	suturing	of	the	peritoneal	muscle	271 layer	and	securing	the	skin	with	Michel	clips,	the	abdominal	cavity	was	flushed	with	272 saline	to	remove	any	excess	FB.	Post-operative	care	(monitoring	body	weight	and	soft	273 diet)	and	analgesia	(buprenorphine	0.05-0.1	mg/kg	daily)	was	provided	for	the	274 
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duration	of	the	protocol.	Three	to	five	days	after	surgery,	mice	were	humanely	killed	by	275 concussion	of	the	brain	and	cervical	dislocation	of	the	neck,	and	thoracolumbar	(TL:	276 T10-L1)	and	lumbosacral	(LS:	L5-S2)	dorsal	root	ganglia	(DRGs)	were	harvested	and	277 cultured	separately	for	gene	expression	experiments.	Dissected	ganglia	were	incubated	278 at	37°C	(in	5%	CO2)	in	Lebovitz	L-15	Glutamax	(GIBCO,	UK)	media	containing	1mg/ml	279 collagenase	type	1A	(Sigma)	and	6mg/ml	bovine	serum	albumin	(BSA;	Sigma,	UK)	for	280 15	min,	followed	by	L-15	media	containing	1mg/ml	trypsin	(Sigma,	UK)	and	6mg/ml	281 BSA	for	30	min.	Ganglia	were	gently	triturated	and	collected	by	brief	centrifugation	at	282 500	g.	The	supernatant	(containing	dissociated	cells)	was	collected	and	the	cycle	of	283 gentle	trituration	and	centrifugation	repeated.	Cells	from	TL	and	LS	DRG	were	plated	284 separately	onto	poly-D-lysine–coated	coverslips	(BD	Biosciences,	UK)	and	incubated	in	285 Lebovitz	L-15	Glutamax	media	containing	2	%	penicillin/streptomycin,	24	mM	NaHCO3,	286 38mM	glucose	and	10	%	fetal	bovine	serum.	Fast	Blue	positive	colonic	sensory	neurons	287 were	individually	harvested	from	cultures	of	retrogradely	labelled	DRG	(either	TL:	T10-288 L1	or	LS:	L5-S2)	by	pulled	glass	pipette.	By	breaking	the	pipette	tip	(containing	the	cell)	289 into	a	tube	containing	preamplification	mastermix	(2.5μl	0.2x	primer/probe	mix,	5μl	290 CellDirect	2x	reaction	buffer	(Invitrogen),	0.1	μl	SUPERase-in	(Ambion,	TX,	USA),	1.2	μl	291 TE	buffer	(Applichem,	Germany)	and	0.2	μl	Superscript	III	Reverse	292 Transcriptase/Platinum	Taq	mix	(Invitrogen))	and	freezing	immediately,	mRNA	293 transcripts	were	preserved.	Only	those	individual	Fast	Blue	positive	neurons	free	from	294 debris	and	other	non-neuronal	cells	(e.g.	satellite	glia)	were	collected.	An	image	of	each	295 harvested	neuron	was	also	captured	using	a	camera	(DCC1545M,	ThorLabs	Inc,	NJ,	USA)	296 attached	to	the	inverted	microscope	enabling	an	estimation	of	cell	size	to	be	297 ascertained.	In	the	absence	of	cells,	samples	of	the	bath	solution	were	collected	for	no-298 template	control	experiments.	Using	the	following	thermal	cycling	protocol,	299 
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preamplification	of	cDNA	was	achieved:	50°C	for	30	minutes,	95°C	for	2	minutes,	then	300 21	cycles	of	(95°C	for	15	seconds,	60°C	for	4	minutes).	After	dilution	(1:5	TE	buffer),	301 Taqman	qPCR	assays	were	run	for	each	gene	of	interest	(Taqman	Assay	ID:	NaV1.1,	302 Mm00450580_m1;	NaV1.2,	Mm01270359_m1;	NaV1.3,	Mm00658167_m1;	NaV1.4,	303 Mm00500103_m1;	NaV1.5,	Mm01342518_m1;	NaV1.6,	Mm00488110_m1;	NaV1.7,	304 Mm00450762_s1;	NaV1.8,	Mm00501467_m1;	NaV1.9,	Mm00449367_m1;	GAPDH,	305 Mm99999915_g1;	Applied	Biosystems)	using	the	following	cycling	protocol:	50°C	for	2	306 minutes,	95°C	for	10	minutes,	then	40	cycles	of	(95°C	for	15	seconds,	60°C	for	1	307 minutes).	Glyceraldehyde-3-phosphate	dehydrogenase	(GAPDH)	acted	as	an	internal	308 positive	control,	with	all	single-cell	RT-PCR	products	expressing	GAPDH	and	bath	309 control	samples	were	negative	for	all	Taqman	reactions.	Relative	expression	of	NaVs	310 was	normalized	to	GAPDH	quantification	cycles	(CT)	using	2-DCT	formula.	Quantitative	311 assessment	of	gene	expression	was	determined	by	quantification	cycle	values	less	than	312 the	threshold	of	35	being	considered	as	positive.		313 
Ramping	hotplate	pain	behaviors		314 
Behavioral	phenotyping	experiments	were	performed	using	both	male	and	female	mice,	315 and	pharmacology	experiments	were	carried	out	in	male	mice.	Acute	heat	pain	was	316 assessed	using	a	ramping	hotplate	comparable	to	that	used	in	human	standardised	317 quantitative	testing	(QST)	protocols	(Rolke	et	al.,	2006).	Mice	were	acclimatized	in	a	318 chamber	for	6	minutes	daily	for	the	3	days	preceding	dosing.	After	which,	following	a	30	319 second	acclimatization,	the	chamber	floor	was	slowly	heated	from	31°C	at	a	rate	of	320 3.4°C/min	and	the	temperature	and	time	taken	until	observing	a	pain	behavior	was	321 recorded	(behavioral	endpoint;	the	occurrence	of	either	licking	or	shaking	of	the	hind	322 paw	and/or	rapid	shifting	of	weight	(stomping)	from	one	foot	to	the	other).	After	323 
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baseline	measurements	were	made,	mice	were	dosed	via	oral	administration	(P.O.)	with	324 either	vehicle	or	PF-5198007	at	1	or	3mg/ml	with	a	dose	volume	of	10ml/kg	and	1hr	325 later,	the	ramping	hotplate	repeated.	Mice	were	humanely	killed	by	concussion	of	the	326 brain	and	cervical	dislocation	of	the	neck	immediately	after	final	assessment	of	thermal	327 pain	threshold.	328 
Skin-nerve	preparation	329 Multi-unit	extracellular	afferent	recordings	were	made	from	the	tibial	nerve	innervating	330 the	glaborous	skin	of	the	hind	paw	as	previously	described	(Milenkovic	et	al.,	2008)	but	331 with	some	modifications.	Briefly,	mice	were	humanely	killed	by	concussion	of	the	brain	332 and	cervical	dislocation	of	the	neck,	the	hind	limbs	were	then	shaved,	removed	and	the	333 tibial	nerve	and	associated	glaborous	skin	dissected	free.	The	preparation	was	mounted	334 glaborous	skin	downwards	in	a	recording	chamber	superfused	(10ml/min;	36±1˚C)	335 with	carbogenated	(95%	O2,	5%	CO2)	Krebs	buffer	(in	mM:	NaCl	107,	KCl	3.48,	NaHCO3	336 26.2,	MgSO4(.7H2O)	0.69,	NaH2PO4	1.67,	Na-gluconate	9.64,	sucrose	7.6,	glucose	5.5,	337 CaCl	1.53).	The	epiperineurium	was	removed	from	the	distal	end	of	the	tibial	nerve	and	338 suction	electrode	recordings	comparable	to	those	of	visceral	afferent	activity	were	339 made.	Following	a	60	minute	stabilisation	period,	a	heat	stimulus	(Krebs	perfused	onto	340 the	skin	at	a	focal	point	equivalent	to	the	heel	portion	of	the	paw)	lasting	50	seconds	341 was	applied,	this	increased	in	temperature	from	36˚C	to	52˚C	at	a	rate	of	0.4˚C/second	342 to	mimic	the	noxious	heat	ramp	used	in	vivo.	In	total,	a	series	of	10	heat	stimulations	343 were	performed	at	15	minutes	intervals.	The	first	4	heat	stimulation	formed	the	344 baseline	reading	with	bath	superfusion	of	PF-5198007	(30nM)	or	vehicle	(0.1%	DMSO)	345 initiated	and	maintained	for	the	duration	of	the	next	2	stimulations	(30	minutes),	PF-346 5198007	(100nM)	or	vehicle	(0.1%	DMSO)	for	the	following	2	heat	stimulations	(30	347 minutes)	and	heat	stimulations	9	and	10	carried	out	during	the	superfusion	(15	348 
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minutes)	of	TTX	(100nM	or	300nM)	and	lidocaine	(1mM),	respectively.	In	separate	349 experiments,	the	effect	of	genotype	and	selective	sodium	channel	antagonists	were	350 assessed	in	response	to	a	cold	stimulus	(36	to	6˚C	at	a	rate	of	0.4˚C/second)	delivered	in	351 the	same	manner	as	the	heat	stimulus,	with	comparable	stimulation	and	protocols	as	352 above.	353 
Data	analysis	354 Pain	behaviors	and	mechanical	thresholds	were	compared	across	experimental	groups	355 with	2-way	analysis	of	variance	(ANOVA)	followed	by	the	Bonferroni	post-hoc	test,	356 using	either	SigmaPlot	12.0	(Systat	Software	Inc.,	CA,	USA)	or	Prism	6	(GraphPad	Inc.,	357 USA).	Referred	hyperalgesia,	expressed	as	the	mechanical	threshold	producing	50%	of	358 responses,	was	calculated	using:	50%	mechanical	threshold	(g)	=	[(10	(Xf	+	κδ))	/10],	359 where	Xf	=	value	(in	logarithmic	units)	of	the	final	von	Frey	filament	used;	κ	=	tabular	360 value	for	the	pattern	of	positive/negative	responses;	and	δ	=	mean	difference	(in	log	361 units)	between	stimuli	(Dixon,	1980).	Peak	changes	or	total	sum	firing	of	362 electrophysiological	nerve	activity	in	multi-unit	experiments	were	determined	by	363 subtracting	baseline	firing	(2	minutes	before	distension	or	drug	application)	from	364 increases	in	nerve	activity	following	distension	or	noxious	chemical	superfusion.	365 Estimation	of	cell	size	from	single-cell	images	was	achieved	by	averaging	the	height	and	366 width	of	each	cell	(ImageJ	1.49V	analysis	software,	NIH,	USA).	Total	sum	firing	of	367 electrophysiological	nerve	activity	in	response	to	each	hot	or	cold	stimulation	was	368 obtained	by	subtracting	any	signal	evoked	by	heat/cold	stimulation	in	the	presence	of	369 lidocaine	(1mM).	Expression	data	was	visualized	using	R	and	the	ggplot2	graphics	370 package	(Wickham,	2009).	Statistical	significance	was	set	at	P	<	0.05.	Data	are	displayed	371 as	mean	±	SEM.	372 
Drugs	373 
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Stock	concentrations	of	capsaicin	(1%;	10%	ethanol,	10%	tween,	80%	saline),	mustard	374 oil	(1%;	70%	ethanol,	30%	saline),	cyclophosphamide	(saline),	bradykinin	(10mM;	375 water),	lidocaine	(1M;	water)	and	ATP	(300mM;	water)	were	purchased	from	Sigma-376 Aldrich	and	prepared	as	described.	Tetrodotoxin	(15μg/ml	stock)	was	purchased	from	377 Nanning	Leaf	Pharmaceuticals	(Canada)	and	diluted	in	saline.	PF-5198007	was	378 manufactured	in-house	by	Pfizer	and	solubilized	in	DMSO	at	a	10mM	stock.	For	in	vitro	379 experiments,	PF-5198007	was	applied	at	a	concentration	of	100nM	(ensuring	almost	380 100%	inhibition	of	mouse	NaV1.7	(IC50	5.2nM)	and	selectivity	over	NaV1.1	and	NaV1.6	381 (IC50	149nM	and	174nM,	respectively)(Alexandrou	et	al.,	2016)).	For	in	vivo	studies	PF-382 5198007,	1mg/ml	or	3mg/ml,	was	suspended	in	0.5%	methylcellulose	+	0.1%	Tween-383 80	in	distilled	water.	Doses	of	PF-5198007	were	selected	to	achieve	a	free	plasma	384 concentration	of	~100nM	(littermate:	1mg/kg,	58	±	10	nM,	N	=	5;	3mg/kg,	842	±	91	nM,	385 
N	=	10;	NaV1.7Nav1.8:	1mg/kg,	68	±	12	nM,	N	=	5;	3mg/kg,	634	±	69	nM,	N	=	9).	Vehicle	386 was	dosed	as	a	10ml/kg	solution	of	0.5%	methylcellulose	+	0.1%	Tween-80	in	distilled	387 water.	All	other	compounds	were	diluted	in	appropriate	experimental	buffer	to	working	388 concentrations	on	the	day	of	experimentation,	unless	otherwise	stated.		389 
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Results	390 
Visceral	pain	behaviors	to	colorectal	sensitizing	noxious	stimuli	were	unaffected	391 
by	deletion	of	NaV1.7		392 We	used	a	conditional	NaV1.7	knockout	mouse	strain,	where	floxed	(SCN9A)	NaV1.7	mice	393 were	crossed	with	mice	in	which	Cre	expression	is	driven	by	the	NaV1.8	promotor	394 (NaV1.7Nav1.8)	resulting	in	tissue-specific	ablation	of	NaV1.7	in	sensory	neurons	395 expressing	nociceptive	markers	(Nassar	et	al.,	2004;	Shields	et	al.,	2012).	Capsaicin	acts	396 at	TRPV1	and	will	activate	the	vast	majority	of	visceral	afferent	terminals	(>85%	397 (Christianson	et	al.,	2006;	Malin	et	al.,	2009))	leading	to	neurogenic	inflammation	and	398 prolonged	ongoing	afferent	activity	due	to	sensitization	(Laird	et	al.,	2001;	Laird	et	al.,	399 2002).	Intracolonic	instillation	of	capsaicin	in	littermate	control	mice	led	to	dose-400 dependent	increases	in	observed	pain	behaviors	consisting	of	abdominal	contractions	401 and	licking	(Fig.	1A).	The	deletion	of	NaV1.7	from	NaV1.8-positive	neurons,	however,	did	402 not	attenuate	pain	behaviors	at	either	dose	of	capsaicin	tested	(P	=	0.72,	N	=	6-8,	2-way	403 ANOVA).	In	separate	experiments,	the	potent	algogen	mustard	oil	was	instilled	404 intracolonically	leading	to	the	activation	and	sensitization	of	afferents	and	induction	of	405 localized	tissue	damage	as	previously	described	(Laird	et	al.,	2002).	Substantial	pain	406 behaviors	were	observed	in	both	NaV1.7Nav1.8	and	littermate	controls	(Fig.	1B),	which	407 were	not	significantly	different	in	terms	of	the	magnitude	of	their	response	(P	=	0.79,	N	408 =	6-8,	2-way	ANOVA).	The	time	course	of	pain	behaviours	induced	by	capsaicin	and	409 mustard	oil	did	not	differ	between	littermate	controls	and	NaV1.7Nav1.8	mice.	These	410 findings	show	that	NaV1.7	expressed	in	NaV1.8-positive	neurons	is	not	required	for	the	411 development	of	visceral	pain	or	for	sustained	spontaneous	nociceptor	activity	as	a	412 result	of	sensitization.		413 
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Referred	hyperalgesia	is	a	common	characteristic	of	visceral	pain,	with	the	sensitization	414 of	somatic	structures	in	the	same	metameric	field	to	the	affected	organ	driven	in	part	by	415 spinal	convergence	of	somatic	and	visceral	afferents	inputs	(Cervero,	1983;	Mertz	et	al.,	416 1995).	Whilst	primary	inflammatory	hyperalgesia	has	been	shown	to	be	dependent	on	417 NaV1.7	in	NaV1.8-expressing	neurons,	whether	NaV1.7	contributes	to	the	development	of	418 secondary	hyperalgesia	remains	unstudied.	The	development	of	mechanical	sensitivity	419 of	the	abdomen	in	response	to	intracolonic	instillation	of	either	capsaicin	(0.1%)	or	420 mustard	oil	(0.01%)	was	independent	of	ablation	of	NaV1.7	from	NaV1.8-expressing	421 neurons,	with	50%	withdrawal	thresholds	significantly	reduced	20	minutes	after	422 treatment	irrespective	of	genotype	(capsaicin;	P	<	0.01,	N	=	6-8,	2-way	ANOVA;	mustard	423 oil,	P	<	0.01,	N	=	6-8,	2-way	ANOVA).		424 
Pain	responses	to	cyclophosphamide-induced	cystitis	are	unaffected	by	deletion	425 
of	NaV1.7	426 To	model	bladder	pain/cystitis	in	NaV1.7Nav1.8	mice,	cyclophosphamide	was	427 administered	leading	to	the	progressive	development	of	visceral	pain	behaviors	for	the	428 duration	of	the	4	hour	observation	window.	Cyclophosphamide	treatment	produces	429 mucosal	erosion	and	haemorrhage	of	the	bladder	in	addition	to	edema	(Fraiser	et	al.,	430 1991).	The	development	and	time	course	of	pain	behaviors	observed	did	not	differ	431 between	littermate	controls	and	NaV1.7Nav1.8	mice	to	either	dose	of	cyclophosphamide	432 tested	(Fig.	2A,	P	=	0.93,	N	=	6-8,	2-way	ANOVA).	Indeed	both	NaV1.7Nav1.8	mice	and	433 littermate	controls	also	showed	marked	referred	hyperalgesia	when	tested	4	hours	434 after	cyclophosphamide	treatment	(Fig.	2B).	The	referred	hyperalgesia	did	not	differ	435 dependent	on	genotype	suggesting	that	persistent	activation	of	nociceptors	by	a	436 developing	noxious	chemical	stimuli	is	not	driven	by	a	requirement	for	NaV1.7	to	be	437 present.	438 
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Visceral	afferent	mechanosensitivity	is	blocked	by	TTX	but	is	unaffected	by	439 
deletion	of	NaV1.7	or	blockade	with	a	selective	small-molecule	NaV1.7	antagonist	440 In	order	to	distinguish	between	the	multiple	roles	that	NaV1.7	makes	to	nociceptive	441 processing,	we	investigated	the	contribution	of	NaV1.7	to	mechanosensitivity	and	442 chemosensitivity	at	the	peripheral	terminals	of	sensory	neurons	innervating	the	443 gastrointestinal	tract.	To	do	this	multi-unit	ex	vivo	extracellular	electrophysiological	444 recordings	of	lumbar	splanchnic	nerve	activity	were	made	from	the	distal	colon	of	mice.	445 Tissues	were	dissected	free	and	cannulated	to	enable	mechanical	and	chemical	stimuli	446 to	be	applied	by	luminal	distension	or	bath	superfusion.	Phasic	distension	of	the	colon	447 to	noxious	pressures	(0-80	mm	Hg)	was	used	to	model	mechanical	stimulation	of	the	448 bowel	and	evoke	increased	afferent	firing	for	the	duration	(60	second)	of	the	distension.	449 Consistent	with	previous	reports,	adaptation	in	the	response	to	repeat	stimulation	(at	9	450 minute	intervals)	was	observed	during	subsequent	distensions	with	the	response	451 stabilizing	by	the	fourth	to	sixth	distension	(see	Fig.	3A	&	C)	(Hockley	et	al.,	2014).	In	452 NaV1.7Nav1.8	mice,	there	was	no	significant	difference	in	either	the	initial	peak	distension	453 response	or	in	the	degree	of	tachyphylaxis	observed	during	repeat	distensions	454 compared	to	littermate	controls	(Fig.	3C,	P	=	0.62,	N	=	13-14,	2-way	repeated-measures	455 (RM)	ANOVA).	Previous	studies	have	suggested	that	not	only	the	magnitude,	but	also	456 the	dynamic	quality,	of	the	distension	paradigm	used	may	be	important	for	delineating	457 gut	motor	events,	specifically	noxious	stimuli	(Sengupta	&	Gebhart,	1994;	Booth	et	al.,	458 2008).	Given	the	proposed	role	of	NaV1.7	as	a	threshold	channel	contributing	to	the	459 amplification	of	depolarizing	stimuli	in	sensory	neurons	(Dib-Hajj	et	al.,	2013),	we	used	460 a	slow	ramp	distension	protocol	to	supramaximal	distension	pressures	(0-145	mm	Hg)	461 in	order	to	investigate	the	impact	of	loss	of	NaV1.7	on	responses	across	a	range	of	462 innocuous	and	noxious	distending	pressures.	In	littermate	controls,	afferent	firing	463 
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increased	proportionally	to	intraluminal	pressure	with	a	peak	firing	rate	of	37.5	±	5.7	464 spikes/s	at	145	mm	Hg.	Significantly	less	firing	was	observed	in	NaV1.7Nav1.8	mice	to	465 equivalent	distending	pressures	(at	145	mm	Hg,	25.7	±	4.2	spikes/s;	P	<	0.0001,	N	=	19,	466 2-way	ANOVA).	However,	firing	rates	in	NaV1.7Nav1.8	mice	to	ramp	distension	were	467 unchanged	within	the	physiologically-relevant	0-80	mm	Hg	range	compared	to	controls	468 (P	>	0.05,	Bonferroni’s	post-hoc	analysis).	Within	the	supramaximal	range	(80	-145	mm	469 Hg),	there	was	a	reduction	in	firing,	suggesting	NaV1.7	may	be	involved	in	transducing	470 non-physiological	extremes	of	pressure	in	the	colon	but	not	innocuous	or	even	noxious	471 mechanical	stimuli.		472 Given	that	NaV1.7	is	ablated	only	in	NaV1.8-positive	neurons,	it	is	possible	that	visceral	473 afferents	that	are	both	sensitive	to	noxious	mechanical	stimuli	and	are	negative	for	474 NaV1.8	may	be	contributory	to	the	responses	observed.	In	order	to	test	this	hypothesis,	475 in	a	further	set	of	experiments,	repeat	phasic	distensions	were	continued	and	the	effect	476 of	the	selective	small-molecule	NaV1.7	antagonist	PF-5198007	(100nM)	was	assessed	477 on	responses	in	both	NaV1.7Nav1.8	and	littermate	control	mice.	Responses	in	littermate	478 control	mice	to	repeat	phasic	distensions	were	unchanged	following	pre-incubation	479 with,	and	in	the	presence	of,	100nM	PF-5198007	compared	to	vehicle	(Fig.	3E,	P	=	0.86,	480 
N	=	7,	2-way	RM	ANOVA).	Further,	the	afferent	response	following	application	of	100nM	481 PF-5198007	in	NaV1.7Nav1.8	mice	also	did	not	significantly	differ	from	that	observed	in	482 wild-type	animals	(P	=	0.87,	N	=	6-7,	2-way	RM	ANOVA).	However,	irrespective	of	483 genotype,	application	of	100nM	TTX	to	preparations	did	fully	block	afferent	firing	to	484 noxious	phasic	distension	(Fig.	3E).	Together	this	shows	that	mechanosensitivity	in	485 visceral	afferents	is	dependent	on	TTX-sensitive	voltage-gated	sodium	channels	but	not	486 NaV1.7.	487 
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Loss,	or	antagonism,	of	NaV1.7	does	not	alter	visceral	afferent	responses	to	acute	488 
inflammatory	and	algogenic	mediators	489 To	investigate	the	involvement	of	NaV1.7	in	modulating	visceral	afferent	sensitivity	to	490 inflammatory	and	algogenic	mediators	used	in	our	in	vivo	studies,	capsaicin	and	491 mustard	oil	were	applied	to	distal	colon	preparations	and	visceral	afferent	responses	492 recorded	from	both	littermate	and	NaV1.7Nav1.8	mice,	and	in	the	presence	or	absence	of	493 100nM	PF-5198007.	In	separate	experiments,	bradykinin	and	ATP,	as	inflammatory	494 mediators	typically	present	during	injury	or	infection,	and	that	may	be	evoked	by	495 mustard	oil/cyclophosphamide	treatment	contributing	to	ongoing	nociceptor	496 sensitization	were	also	tested.		497 Responses	to	application	of	500nM	capsaicin	did	not	differ	between	NaV1.7Nav1.8	mice	498 and	littermate	mice	in	vehicle	control	experiments	(0.1%	DMSO;	NaV1.7Nav1.8	vs.	499 littermate;	P	=	0.50,	N	=	6	both	groups,	unpaired	t-test,	Fig.	4A).	In	addition,	superfusion	500 of	100nM	PF-5198007	during,	and	5	minutes	prior	to,	capsaicin	(500nM)	application	501 did	not	significantly	change	the	evoked	afferent	discharge	in	either	genotype	502 (NaV1.7Nav1.8:	100nM	PF-5198007	vs.	0.1%	DMSO,	P	=	0.82,	N	=	6,	unpaired	t-test;	503 littermate:	100nM	PF-5198007	vs.	0.1%	DMSO,	P	=	0.59,	N	=	6,	unpaired	t-test,	Fig.	4A).	504 Afferent	firing	evoked	by	mustard	oil	was	also	unchanged	in	both	NaV1.7Nav1.8	mice	and	505 littermate	controls	(0.1%	DMSO:	NaV1.7Nav1.8	vs.	littermate,	P	=	0.46,	N	=	6,	unpaired	t-506 test,	Fig.	4B),	irrespective	of	the	presence	of	NaV1.7	antagonist	(NaV1.7Nav1.8:	100nM	PF-507 5198007	vs.	0.1%	DMSO,	P	=	0.44,	N	=	6,	unpaired	t-test;	littermate:	100nM	PF-5198007	508 vs.	0.1%	DMSO,	P	=	0.93,	N	=	6,	unpaired	t-test,	Fig.	4B).	509 Bath	superfusion	of	1mM	ATP	in	littermate	mice	resulted	in	significant	afferent	510 discharge	with	a	peak	change	in	firing	of	1.39	±	0.50	spikes/s.	In	NaV1.7Nav1.8	mice,	the	511 response	was	comparable	to	littermate	controls	(2.33	±	0.80	spikes/s,	P	=	0.32,	N	=	7-8,	512 
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unpaired	t-test).	Responses	to	application	of	1μM	bradykinin	were	greater	than	that	513 observed	for	ATP,	however	did	not	differ	dependent	on	genotype	(littermate,	9.11	±	514 3.32	vs.	NaV1.7Nav1.8,	8.56	±	3.04	spikes/s,	P	=	0.90,	N	=	7-8,	unpaired	t-test).	Further,	in	515 distal	colon	preparations	from	littermate	controls	pre-incubated	with	100nM	PF-516 5198007,	peak	firing	response	to	1μM	bradykinin	was	unchanged	(vehicle	(0.1%	517 DMSO)	5.16	±	2.00	versus	100nM	PF-5198007	4.31	±	0.63	spikes/s,	P	=	0.70,	N	=	7,	518 unpaired	t-test);	this	was	also	true	of	tissues	from	NaV1.7Nav1.8	mice	pre-incubated	with	519 the	NaV1.7	antagonist	(100nM	PF-5198007;	P	=	0.17,	N	=	6-7,	unpaired	t-test).	520 Collectively,	these	data	suggest	that	NaV1.7	within	the	peripheral	terminal	of	colonic	521 sensory	neurons	is	not	required	in	order	to	transduce	both	noxious	mechanical	and	522 chemical	algogenic	stimuli,	in	agreement	with	behavioral	experiments.	523 
Localization	of	NaV	expression	in	colonic	sensory	neurons	524 We	next	investigated	the	expression	of	voltage-gated	sodium	channel	α	subunits	525 present	in	colonic	sensory	neurons.	Specifically,	using	single-cell	qRT-PCR	we	examined	526 the	expression	of	mRNA	transcripts	for	NaV1.1,	NaV1.2,	NaV1.3,	NaV1.4,	NaV1.5,	NaV1.6,	527 NaV1.7,	NaV1.8	and	NaV1.9	in	gut-projecting	sensory	neurons.	Both	lumbar	splanchnic	528 and	pelvic	innervation	have	been	shown	to	contribute	to	the	transmission	of	noxious	529 stimuli	from	the	distal	colon	(Brierley	et	al.,	2004).	As	such,	the	expression	of	these	530 channels	was	determined	in	colonic	sensory	neurons	in	dorsal	root	ganglia	(DRG)	T10	531 to	L1	levels	(thoracolumbar:	TL)	that	are	known	to	possess	the	greatest	number	of	532 sensory	neurons	projecting	via	the	lumbar	splanchnic	nerve,	and	separately	in	DRG	L5	533 to	S2	levels	(lumbosacral:	LS);	the	afferents	from	which	have	been	shown	to	project	534 predominantly	via	the	pelvic	nerve.	Of	the	30	cells	collected	per	mouse	(N	=	3),	the	535 average	size	of	colonic	sensory	neurons	harvested	was	32.0	±	0.2	μm	for	TL	(N	=	3)	and	536 30.7	±	1.0	μm	for	LS	(N	=	3).	In	the	NaV1.7Nav1.8	mice	used	in	the	studies	described	here,	537 
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NaV1.7	was	selectively	ablated	from	all	NaV1.8-positive	sensory	neurons.	To	confirm	the	538 proportion	of	colonic	sensory	neurons	affected	by	this	gene	ablation,	the	expression	of	539 NaV1.7	and	NaV1.8	was	first	examined.	NaV1.7	was	present	in	100%	of	thoracolumbar	540 and	95.6	±	2.22%	of	lumbosacral	colonic	sensory	neurons.	High	expression	of	NaV1.8	541 was	also	observed	in	both	thoracolumbar	(95.6	±	2.22	%)	and	lumbosacral	(91.1	±	4.44	542 %)	colonic	sensory	neuron	populations.	Importantly,	significant	co-expression	of	both	543 these	sodium	channels	in	individual	colonic	sensory	neurons	was	found,	with	95.4%	of	544 NaV1.7-positive	neurons	also	expressing	NaV1.8,	suggesting	that	the	vast	majority	of	545 colonic	sensory	neurons	in	NaV1.7Nav1.8	mice	would	be	affected	by	the	genetic	deletion.	546 The	expression	of	the	remaining	tetrodotoxin-sensitive	(TTX-S:	NaV1.1,	NaV1.2,	NaV1.3,	547 NaV1.4	and	NaV1.6)	and	TTX-resistant	voltage-gated	sodium	channels	(TTX-R:	NaV1.5	548 and	NaV1.9)	was	also	determined	(Catterall	et	al.,	2005).	Of	the	TTX-S	sodium	channels,	549 NaV1.6	was	present	in	the	greatest	frequency	(86.7%;	Fig.	5A)	of	thoracolumbar	colonic	550 sensory	neurons	after	NaV1.7.	Significant	proportions	of	thoracolumbar	colonic	sensory	551 neurons	also	expressed	either	NaV1.1	(44.4	±	5.88	%),	NaV1.2	(68.9	±	8.89	%)	or	NaV1.3	552 (53.3	±	10.2	%),	although	co-expression	was	not	always	observed	(see	Fig.	5C).	As	553 expected,	both	the	skeletal	myocyte	voltage-gated	sodium	channel	NaV1.4	and	the	554 cardiac	myocyte	NaV1.5	channel	were	expressed	by	low	proportions	of	thoracolumbar	555 colonic	sensory	neurons	(6.67	±	6.67	%	and	17.8	±	5.88	%,	respectively).	In	agreement	556 with	previous	studies,	mRNA	transcripts	for	TTX-R	NaV1.9	were	observed	in	84.4	±	44.4	557 %	of	thoracolumbar	neurons	(Hockley	et	al.,	2016).	By	comparison,	the	expression	of	558 NaV1.1,	NaV1.2,	NaV1.3,	NaV1.4,	NaV1.7	and	NaV1.8	did	not	significantly	differ	between	559 populations	of	lumbosacral	compared	to	thoracolumbar	colonic	sensory	neurons	(Fig.	560 5A,	all	P	>	0.05,	TL	vs.	LS,	unpaired	t-test).	Interestingly,	significant	differences	were	561 observed	between	the	frequency	of	expression	of	NaV1.5	(TL	vs.	LS,	P	<	0.05,	unpaired	t-562 
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test)	and	NaV1.6	(TL	vs.	LS,	P	<	0.01,	unpaired	t-test)	in	lumbosacral	compared	to	563 thoracolumbar	colonic	sensory	neurons.	Indeed,	transcripts	for	both	NaV1.5	and	NaV1.6	564 were	observed	in	approximately	half	of	lumbosacral	colonic	sensory	neurons	(48.9	±	565 8.01	%	and	51.1	±	5.88	%,	respectively).	The	expression	of	NaV1.9	(which	has	been	566 shown	previously	to	contribute	to	afferent	sensitivity	of	the	lumbar	splanchnic	567 nerve(Hockley	et	al.,	2014))	in	lumbosacral	colonic	sensory	neurons	were	consistent	568 with	the	frequency	of	expression	observed	in	the	thoracolumbar	populations	(P	=	0.42,	569 
N	=	3,	unpaired	t-test).	Taken	together,	these	data	not	only	support	the	expression	of	570 NaV1.7	by	a	majority	of	colonic	sensory	neurons	innervating	the	distal	colon,	but	also	571 highlight	an	as	yet	unexplored	complexity	in	the	molecular	patterning	of	voltage-gated	572 sodium	channels	present	in	these	neurons.		573 
Deletion	of	NaV1.7	impairs	somatic	noxious	thermal	thresholds,	which	can	be	574 
recapitulated	by	NaV1.7	antagonism	575 Given	that	no	differences	in	acute	visceral	pain	or	referred	hyperalgesia	could	be	576 observed	in	mice	lacking	NaV1.7	in	NaV1.8-positive	neurons	or	to	block	of	NaV1.7	by	the	577 selective	inhibitor	PF-5198007,	we	next	sought	to	investigate	the	role	of	NaV1.7	in	578 somatic	acute	pain	behaviors.	In	order	to	investigate	the	contribution	of	NaV1.7	in	579 NaV1.8-positive	sensory	neurons	to	the	modulation	of	thermal	thresholds,	we	utilized	a	580 ramping	hotplate	behavioral	paradigm.	In	littermate	controls,	this	latency	was	261	±	5	581 seconds	(N	=	38)	corresponding	to	a	temperature	rise	of	~13.6°C	(baseline	floor	582 temperature	31°C	ramping	to	44.6	±	0.2°C;	Fig.	6A).	This	increase	in	temperature	583 required	to	evoke	a	behavioral	response	was	equivalent	to	a	previous	study	using	a	584 modified	ramping	Hargreaves’	test	(Minett	et	al.,	2014a).	NaV1.7Nav1.8	mice	showed	an	585 attenuated	response	to	ramping	hotplate	with	an	augmented	latency	(274	±	5	s)	and	586 significantly	increased	thermal	threshold	(46.1	±	0.3°C,	N	=	36,	P	<	0.0001,	unpaired	t-587 
27	
	
test;	Fig.	6A)	in	agreement	with	previous	observations	(Minett	et	al.,	2014a).	The	588 attenuation	of	complex	behaviors	associated	with	the	ramping	hotplate	test	suggests	589 involvement	of	NaV1.7	in	pain	signalling	to	noxious	thermal	stimulation	of	the	skin	590 under	certain	conditions.		591 Using	the	ramping	hotplate,	we	went	on	to	confirm	the	ability	for	the	selective	NaV1.7	592 inhibitor	PF-5198007	to	modulate	thermal	pain	behaviors	(see	Fig.	6B).	In	littermate	593 mice,	application	of	PF-5198007	(1mg/kg	P.O.)	significantly	increased	the	thermal	594 threshold	for	observing	pain	behaviors	with	a	concomitant	increase	in	the	latency	to	595 response	when	compared	to	vehicle	controls	(P	<	0.01,	N	=	10,	2-way	ANOVA	with	596 Bonferroni’s	post-hoc	vs.	vehicle;	Fig.	6B).	In	both	vehicle	and	PF-5198007	treatment	597 groups,	the	thermal	threshold	of	NaV1.7Nav1.8	mice	remained	significantly	greater	than	598 littermate	controls	but	did	not	differ	between	groups.	Application	of	a	higher	dose	of	599 PF-5198007	(3mg/kg	P.O.)	also	led	to	an	increase	in	thermal	threshold	during	hotplate	600 ramp,	which	was	comparable	to	thresholds	observed	in	NaV1.7Nav1.8	mice	and	601 significantly	different	from	vehicle	groups	(P	<	0.05,	N	=	10,	2-way	ANOVA	with	602 Bonferroni’s	post-hoc	vs.	vehicle).	These	data	suggest	that	whilst	pain	behaviors	can	be	603 evoked	in	the	absence,	or	antagonism,	of	NaV1.7,	the	expression	of	NaV1.7	in	sensory	604 neurons	modulates	heat	pain	thresholds	to	noxious	thermal	stimuli.	605 
NaV1.7	also	contributes	to	cutaneous	afferent	firing	to	both	noxious	hot,	but	not	606 
cold,	thermal	stimuli	607 To	investigate	whether	NaV1.7	was	necessary	for	sensory	transduction	at	the	peripheral	608 terminal	of	somatic	afferents,	ex	vivo	multi-unit	electrophysiological	recordings	of	the	609 tibial	nerve	from	skin-nerve	preparations	of	NaV1.7Nav1.8	mice	and	littermate	controls	610 were	made	(Fig.	6C	&	D).	In	support	of	hotplate	experiments,	a	ramping	thermal	stimuli	611 (focal	water	jet	from	36°C	to	52°C	(at	~0.4°C/sec))	was	applied	to	the	corium	side	of	the	612 
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skin	and	the	evoked	nerve	activity	recorded.	Total	firing	during	the	heat-evoked	stimuli	613 was	significantly	attenuated	in	NaV1.7Nav1.8	mice	compared	to	littermate	controls	(Fig.	614 6E,	P	<	0.0001,	N	=	26-29,	2-way	ANOVA	with	Bonferroni’s	post-hoc).	Bath	superfusion	615 of	100nM	TTX	led	to	significant	inhibition	of	firing	regardless	of	genotype	compared	to	616 vehicle	controls	(Fig.	6E,	P	<	0.05,	N	=	9-11	and	P	<	0.0001,	N	=	10-11,	NaV1.7Nav1.8	and	617 littermate	controls,	respectively,	2-way	ANOVA	with	Bonferroni’s	post-hoc),	suggesting	618 that	the	transduction	of	noxious	thermal	stimuli	at	the	peripheral	terminal	of	sensory	619 afferents	is	enhanced	by	the	presence	of	NaV1.7	in	NaV1.8-positive	neurons,	but	is	620 dependent	on	other	TTX-S	NaVs	that	might	be	present.	Application	of	100nM	PF-621 5198007	in	littermate	controls	was	able	to	recapitulate	the	attenuated	response	622 observed	in	NaV1.7Nav1.8	mice	(Fig.	6F,	P	<	0.05,	N	=	9-10,	2-way	ANOVA	with	623 Bonferroni’s	post-hoc	vs.	vehicle	(0.1%	DMSO)).	In	addition,	PF-5198007	in	NaV1.7Nav1.8	624 mice	further	reduced	afferent	responses	to	heat	ramp	suggesting	that	afferent	firing	at	625 the	peripheral	terminal	is	dependent	predominantly	on	expression	of	NaV1.7	in	NaV1.8-626 positive	sensory	neurons.	However,	this	does	not	discount	contributions	of	NaV1.7	to	627 other	sensory	populations	spinally	or	supra-spinally	involved	in	the	nociceptive	628 processing	of	thermal	stimuli.		629 In	addition,	we	investigated	cutaneous	afferent	firing	to	evoked	cold	stimuli	by	localized	630 perfusion	of	a	cooling	perfusate	over	the	receptive	field	from	36°C	to	~6°C	(at	631 ~0.4°C/sec).	In	previous	studies,	NaV1.7	has	been	shown	to	be	involved	in	acetone-632 induced	cooling,	but	not	noxious	cold	sensation	(Minett	et	al.,	2012).	Responses	evoked	633 by	cold	stimulation	of	the	skin	did	not	differ	between	NaV1.7Nav1.8	mice	and	littermate	634 controls	(Fig.	6G,	P	>	0.05,	N	=	18,	2-way	ANOVA	with	Bonferroni’s	post-hoc),	however	635 application	of	100nM	TTX	completely	abolished	cold-evoked	responses	compared	to	636 vehicle	(P	<	0.01,	N	=	6	and	P	<	0.0001,	N	=	5-6,	littermate	and	NaV1.7Nav1.8	mice,	637 
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respectively,	2-way	ANOVA	with	Bonferroni’s	post-hoc).	Finally	incubation	with	the	638 selective	NaV1.7	antagonist	PF-5198007	(100nM)	did	not	significantly	attenuate	cold	639 evoked	afferent	firing	(Fig.	6H),	supporting	the	posit	that	NaV1.7	does	not	contribute	to	640 the	transduction	or	amplification	of	cold-evoked	depolarizations	at	the	peripheral	641 terminal.	642 
Mesenteric	nerve	responses	to	phasic	distension	in	human	appendix	are	643 
unaffected	by	inhibition	of	NaV1.7	644 Finally,	in	order	to	understand	whether	our	findings	in	murine	visceral	afferents	645 translate	to	human	we	used	ex	vivo	extracellular	recordings	of	surgically	resected	646 appendices	to	investigate	NaV1.7	function	in	response	to	mechanical	stimuli.	The	human	647 appendix	has	been	used	previously	as	a	pre-clinical	model	of	visceral	nociception	(Peiris	648 
et	al.,	2011).	The	appendix	was	cannulated	and	stimulated	by	repeat	noxious	ramp	649 distension	(0-60	mm	Hg)	and	mesenteric	nerve	firing	recorded.	Ramp	distension	650 evoked	a	concomitant	increase	in	human	visceral	afferent	firing	with	a	peak	change	in	651 firing	of	10.1	±	1.5	spikes/s	(N	=	5),	with	reproducible	responses	observed	to	652 subsequent	distensions.	Application	of	PF-5198007	did	not	significantly	impair	visceral	653 afferent	firing	to	ramp	distension	at	either	low	or	high	distending	pressures	(Fig.	7B,	P	=	654 0.26,	N	=	5,	2-way	RM	ANOVA).	This	confirms	our	mouse	data	highlighting	that	NaV1.7	655 appears	not	to	significantly	impact	visceral	afferent	sensitivity	to	acute	656 mechanosensation.	As	such,	NaV1.7	imparts	functionality	on	sensory	neurons	in	a	657 modality-specific	manner	and	therefore	the	analgesic	assessment	of	NaV1.7	antagonists	658 should	be	determined	in	a	mechanism-dependent	fashion.						659 	660 
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Discussion	661 Nociceptive	processing	in	somatic	and	visceral	pain	has	common	underlying	pathways,	662 including	convergence	in	neuroanatomy,	overlap	in	psychological	representation	and	663 commonality	in	cellular	transductions.	However,	important	differences	exist	in	the	664 manifestation,	perception	and	psychology	of	these	pain	modalities.	Traditionally,	665 visceral	afferents	are	characterized	based	on	mechanical	sensitivity	and	activation	by	666 chemical	mediators	(including	bradykinin	and	ATP	(Su	&	Gebhart,	1998;	Brierley	et	al.,	667 2004;	Grundy,	2004)),	with	functional	assessment	required	to	define	nociceptive	668 properties.	Compared	to	somatic	counterparts,	visceral	sensory	neurons	almost	669 exclusively	possess	characteristics	attributed	to	nociceptors	(unmyelinated	C-fibres	670 (Sengupta	&	Gebhart,	1994),	peptidergic	(Robinson	et	al.,	2004)	and	high	expression	of	671 NaV1.8/TTX-R	sodium	currents	(Beyak	et	al.,	2004)),	yet	collectively	transduce	672 innocuous	unconscious	and	conscious	sensations	in	addition	to	pain.	As	such,	visceral	673 sensory	neurons	do	not	fit	well	with	classical	views	of	nociceptors	and	established	674 schema	for	nociceptive	transduction	pathways.			675 Here,	we	add	to	this	by	showing	that	visceral	pain	signalling	in	vivo	to	acute	and	676 sensitizing	noxious	stimuli	is	independent	of	NaV1.7.	We	confirm	by	way	of	ex	vivo	677 electrophysiological	recordings	of	mouse	visceral	afferent	fibres	that	deletion	of,	or	678 selective	small-molecule	antagonism	of	NaV1.7,	does	not	attenuate	responses	to	679 persistent	noxious	mechanical	(including	repeat	phasic	and	sustained	ramp	distension)	680 and	chemical	stimuli	(including	capsaicin,	mustard	oil,	bradykinin	and	ATP).	This	lack	of	681 efficacy	in	NaV1.7	antagonism	in	blocking	visceral	afferent	activation	extends	to	682 recordings	from	resected	human	appendix	tissues	when	applying	noxious	distending	683 pressures.	Surprisingly,	mouse	visceral	sensory	neurons	almost	always	express	NaV1.7	684 suggesting	that,	whilst	present,	NaV1.7	appears	not	to	contribute	to	the	modulation	of	685 
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afferent	excitability	to	depolarizing	stimuli,	or	the	propagation	of	action	potentials.	686 Furthermore,	the	lack	of	phenotype	observed	in	NaV1.7Nav1.8	mice	suggests	NaV1.7	is	not	687 necessary	for	transducing	noxious	visceral	input	centrally	by	NaV1.8-expressing	688 neurons.	By	contrast	somatically,	deletion	of	NaV1.7	does	modulate	acute	heat	pain	689 thresholds,	which	can	be	replicated	using	selective	NaV1.7	antagonism.	Strikingly,	loss	of	690 NaV1.7	from	NaV1.8-expressing	neurons,	or	small-molecule	antagonism,	are	able	to	691 attenuate	afferent	firing	evoked	by	ramping	heat	stimuli	applied	to	skin-nerve	692 preparations.	This	implicates	NaV1.7	in	modulating	thermal	transduction	sensitivity	in	693 somatic	afferents.	This	was	not	true	of	cold	stimuli,	where	NaV1.7	does	not	have	a	role	in	694 afferent	responses.	Our	data	demonstrates	that	whilst	NaV1.7	does	modulate	defined	695 somatic	pain	pathways,	it	is	not	required	for	those	visceral	pain	modalities	investigated	696 here	and	advocates	that	selective	pharmacological	block	of	NaV1.7	in	the	viscera	may	697 prove	ineffective	in	targeting	chronic	visceral	pain	caused	by	spontaneous	nociceptor	698 activity,	sensitizing	inflammatory	mediators	or	evoked	mechanical	distension:	principal	699 clinical	drivers	of	visceral	pain.	700 Voltage-gated	sodium	channels	are	vital	for	the	transmission	of	painful	stimuli	in	701 primary	afferents.	Importantly,	the	relative	significance	of	individual	sodium	channels	is	702 dependent	on	the	pain	modality	considered,	with	NaV1.7	essential	in	transducing	703 somatic	acute	thermal	and	mechanical	pain,	in	conjunction	to	inflammatory	704 hyperalgesia	and	neuropathic	allodynia	(Minett	et	al.,	2014b).	Similarly,	NaV1.8	is	705 critical	for	extreme	cold	pain	(Abrahamsen	et	al.,	2008),	with	chemotherapy-induced	706 allodynia	dependent	on	NaV1.6	(Sittl	et	al.,	2012;	Deuis	et	al.,	2013).	Normal	visceral	707 nociceptor	activity,	by	contrast,	is	dependent	on	both	NaV1.8	(Laird	et	al.,	2002)	and	708 NaV1.9	(Hockley	et	al.,	2014).	Surprisingly,	the	role	of	NaV1.7	in	visceral	pain	processing	709 is	poorly	understood	in	spite	of	human	genetic	data	linking	NaV1.7	to	pain	signalling.		710 
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Substantive	evidence	for	the	involvement	of	NaV1.7	in	visceral	pain	processing	comes	711 from	human	genetic	studies.	Patients	with	congenital	insensitivity	to	pain	linked	to	712 mutations	in	NaV1.7	do	not	feel	pain,	including	pain	originating	from	internal	structures	713 (broken	bones	(Cox	et	al.,	2006;	Goldberg	et	al.,	2007))	and	hollow	organs	(e.g.	during	714 appendicitis	or	child-birth	(Melzack	&	Wall,	1988;	Zimmermann	et	al.,	1988)).	715 Mutations	in	SCN9A	gene	encoding	NaV1.7	are	also	causal	in	paroxysmal	extreme	pain	716 disorder	(PEPD)	where	severe	burning	pain	may	occur	in	rectal,	ocular	and	mandibular	717 regions.	Intriguingly,	defecation	and	micturition	can	both	trigger	such	rectal	pain	718 attacks	(Fertleman	et	al.,	2006;	Meglic	et	al.,	2014),	implicating	hypersensitivity	of	719 visceral	mechanoreceptors	in	initiating	pain	attacks.	Whilst	NaV1.7	is	linked	with	720 multiple	aspects	of	the	pain	pathway,	this	is	the	first	report	detailing	the	contribution	of	721 NaV1.7	to	visceral	pain	processing.	Using	single-cell	qRT-PCR	of	gut-specific	sensory	722 neurons	we	show	that	mRNA	transcripts	for	NaV1.7	are	expressed	by	the	vast	majority	723 of	colonic	sensory	neurons,	consistent	with	NaV1.7	immunoreactivity	in	extrinsic	724 afferent	terminals	of	the	distal	colorectum	(Feng	et	al.,	2015).	Co-expression	of	NaV1.7	725 in	NaV1.8-positive	neurons	was	substantial	in	gut-projecting	populations,	suggesting	726 that	nearly	all	visceral	sensory	neurons	would	be	affected	by	NaV1.8-specific	knockout	727 of	NaV1.7	(Nassar	et	al.,	2004).	However,	it	is	possible	that	some	NaV1.7-positive	NaV1.8-728 negative	colonic	neurones	remain,	which	may	be	sufficient	to	maintain	pain	behaviours.	729 Visceral	afferent	firing	to	mechanical	and	chemical	activation	were	unaffected	following	730 loss	of,	or	antagonism	of,	NaV1.7,	but	could	be	blocked	by	TTX	as	shown	previously	731 (Campaniello	et	al.,	2016).	As	such,	TTX-S	NaVs	other	than	NaV1.7	are	involved	in	732 transducing	noxious	visceral	stimuli.	Established	roles	for	TTX-R	NaV1.8	and	NaV1.9	733 correlate	well	with	their	extensive	expression	shown	here;	however	little	is	known	734 about	the	expression	of	TTX-S	NaVs	within	a	viscerally-projecting	population.	NaV1.6	is	735 
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essential	in	pelvic	afferent	endings	for	spike	initiation	and	repetitive	firing	(Feng	et	al.,	736 2015),	a	concept	that	would	fit	with	the	extensive	presence	of	NaV1.6	mRNA	transcripts	737 observed	here.	Further,	using	toxin	antagonists	of	NaV1.7	(ProTx-II)	and	NaV1.6	(μ-738 conotoxin	GIIIa	and	μ-conotoxin	PIIIa),	a	requirement	on	NaV1.6,	but	not	NaV1.7,	was	739 observed	for	the	encoding	of	stretch-sensitive	pelvic	afferents	(Feng	et	al.,	2015).	Taken	740 together,	these	observations	present	compelling	evidence	that	NaV1.7	is	redundant	in	741 visceral	afferent	nociception	to	spontaneous	or	evoked	noxious	stimuli.		742 Clearly	whilst	not	necessary	for	normal	sensation	in	the	gut,	the	high	relative	expression	743 of	NaV1.7	suggests	that	aberrant	NaV1.7	function,	such	as	that	present	in	some	744 monogenic	pain	disorders,	could	significantly	impact	visceral	sensation.	Intriguingly,	745 the	propensity	for	mutations	in	NaV1.7	to	evoke	regional	pain	phenotypes	in	PEPD	746 patients	(i.e.	rectal	and	not	‘true	visceral’	pain)	could	be	driven	by	differences	we	747 observe	here	in	the	expression	of	some	sodium	channels	(NaV1.5(Renganathan	et	al.,	748 2002)	and	NaV1.6(Cummins	et	al.,	2005))	located	in	thoracolumbar,	versus	lumbosacral,	749 visceral	sensory	neurons.	Precedent	for	background	neuronal	phenotype	contributing	750 to	the	manifestation	of	functional	effects	already	exists	with	the	same	mutation	in	751 NaV1.7	causing	hypo-	and	hyper-excitability	when	expressed	in	either	sympathetic	or	752 sensory	neurons	(Rush	et	al.,	2006).	The	extensive	expression	of	NaV1.7	suggests	that	753 mutations	subverting	its	endogenous	function	may	significantly	alter	phenotype	even	if	754 not	required	for	that	pain	modality	normally.	As	such	it	is	possible	that	non-canonical	755 roles	of	NaV1.7	may	help	explain	the	contradiction	of	how	CIP	patients	associated	with	756 loss	of	NaV1.7	do	not	feel	visceral	pain.	For	example,	recent	evidence	of	NaV1.7	deletion	757 upregulating	endogenous	opioid	expression	suggests	a	complex	transcriptional	758 modulatory,	as	well	as	electrogenic,	contribution	by	NaV1.7,	however	this	did	not	alter	759 the	expression	of	other	NaV	subtypes	present	in	DRG	(Minett	et	al.,	2015).	Importantly,	760 
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the	use	of	a	selective	small-molecule	antagonist	of	NaV1.7	enables	us	to	discount	761 developmental	differences	in	gene	deletion	studies	in	the	phenotypes	observed	here.	762 Comparison	with	somatic	pain	behaviors	enables	confirmation	of	a	modality-specific	763 action	for	NaV1.7	expression	and	confirms	the	ability	of	the	antagonist	PF-5198007	in	764 replicating	gene	deletion	studies.	NaV1.7	is	required	for	modulating	heat	pain	765 thresholds	after	burn	injury	(Shields	et	al.,	2012)	and	for	acute	noxious	heat	sensing	in	a	766 population	of	NaV1.8-negative	neurons	(Minett	et	al.,	2012).	Surprisingly,	we	found	767 using	an	adapted	ramping	hotplate	test	that	loss	of	NaV1.7	from	NaV1.8-positive	neurons	768 could	also	alter	acute	heat	pain	thresholds	and	this	could	be	recapitulated	using	PF-769 5198007.	In	all	cases,	mice	remained	sensitive	to	noxious	heat,	suggesting	that	NaV1.7	is	770 not	required	in	NaV1.8-expressing	neurons	but	can	modulate	the	thermal	threshold	771 sensitivity.	Notably,	we	observed	a	desensitization	of	the	heat	pain	threshold	from	772 ~44°C	by	2-3°C	following	antagonism	of	NaV1.7,	as	such	fixed	temperature	hotplate	773 tests	typically	used	to	measure	withdrawal	latencies	at	50°C	or	55°C	would	be	above	774 threshold	in	either	case	masking	potential	phenotypic	differences.	A	similar	non-775 redundant	role	for	NaV1.7	in	NaV1.8-expressing	neurons	was	observed	to	an	adapted	776 Hargreaves’	test	(Minett	et	al.,	2014a).	This	further	highlights	the	involvement	of	777 multiple	sub-populations	of	neurons	on	stimulus-intensity	specific	responses	778 underpinning	noxious	thermal	detection.	779 In	summary,	using	a	combination	of	gene	deletion	knockout	mice	and	pharmacological	780 tool	molecule	we	demonstrate	that	NaV1.7,	although	expressed	extensively	by	gut-781 projecting	sensory	neurons,	contributes	minimally	to	visceral	pain	pathways	associated	782 with	algogenic	sensitizing	chemicals	and	evoked	activation	of	visceral	afferents	by	783 noxious	stimuli.	The	patterning	of	sodium	channel	expression	shown	here	reveals	a	784 previously	unstudied	molecular	complexity	to	visceral	sensory	neurons.	Combined	with	785 
35	
	
a	detailed	study	of	somatic	thermal	sensitivity,	we	show	that	assessment	of	candidate	786 analgesic	targets	to	pain	mechanisms	must	be	considered	in	a	modality-specific	manner.	787 As	such,	NaV1.7	antagonism	of	peripheral	visceral	afferents	may	not	represent	a	viable	788 therapeutic	rationale	for	the	treatment	of	chronic	visceral	pain	associated	with	evoked	789 distension	or	inflammation	of	the	viscera.		790 
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Figure	Legends	791 Table	1		792 Patients	details	from	which	resected	appendix	specimens	were	used.	Appendix	793 specimens	from	5	patients	were	collected	and	used	in	electrophysiological	nerve	794 recordings.			795 Figure	1	796 Spontaneous	visceral-pain	related	behaviors	in	NaV1.7Nav1.8	and	littermate	mice	797 following	intracolonic	administration	of	capsaicin	(A	and	C)	or	mustard	oil	(B	and	D).	798 Number	of	acute	pain	related	behaviors	(licking	of	abdomen,	stretching,	abdominal	799 retractions)	induced	by	capsaicin	(A)	or	mustard	oil	(B)	during	a	20	min	period.	800 Referred	mechanical	hyperalgesia	(evaluated	by	stimulation	of	the	abdomen	with	von	801 Frey	filaments)	was	measured	20	min	after	the	administration	of	capsaicin	(C)	or	802 mustard	oil	(D).	Mean	±	SEM	of	values	obtained	in	6-10	animals.	*P	<	0.05	and	**P	<	803 0.01	vs.	vehicle.	804 Figure	2	805 Visceral	pain	related	behaviors	evoked	by	cyclophosphamide-induced	cystitis	in	806 NaV1.7Nav1.8	and	littermate	mice.	(A)	Behavioral	pain	responses	were	recorded	at	30	807 minute	intervals	during	the	240	min	observation	period	after	cyclophosphamide	808 injection.	(B)	Referred	mechanical	hyperalgesia	was	evaluated	by	stimulation	of	the	809 abdomen	with	von	Frey	filament	4h	after	cyclophosphamide	administration.	Mean	810 ±	SEM	of	values	obtained	in	6-10	animals.	*P	<	0.05	and	**P	<	0.01,	vs.	vehicle.	811 	812 Figure	3	813 Visceral	afferent	responses	to	noxious	distension	of	the	distal	colon	in	NaV1.7Nav1.8	mice	814 and	following	small-molecule	NaV1.7	antagonism.	Example	rate	histogram	of	colonic	815 
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splanchnic	nerve	activity	and	intraluminal	pressure	trace	to	repeat	phasic	distension	(0-816 80	mm	Hg;	60	s;	9	min	intervals)	in	NaV1.7Nav1.8	(B)	and	littermate	(A)	mice.	(C)	Peak	817 change	in	firing	rate	during	phasic	distensions	in	both	genotypes	(P	=	0.46,	2-way	818 repeated-measures	ANOVA).	(D)	Average	firing	rates	to	ramp	distension	(0-145	mm	819 Hg)	at	5	mm	Hg	increments	in	littermate	and	NaV1.7Nav1.8	mice.	(E)	Effect	of	100nM	PF-820 5198007,	vehicle	(0.1%	DMSO)	or	100nM	TTX	on	total	firing	evoked	during	repeat	0-80	821 mm	Hg	phasic	distensions	in	littermate	and	NaV1.7Nav1.8	mice.		822 Figure	4	823 Effect	of	capsaicin	and	mustard	oil	on	visceral	afferent	responses.	Change	in	peak	firing	824 rate	to	application	of	500nM	capsaicin	(A)	and	250μM	mustard	oil	(B)	in	littermate	and	825 NaV1.7Nav1.8	mice,	both	in	the	absence	and	presence	of	100nM	PF-5198007.		826 Figure	5	827 Expression	of	voltage-gated	sodium	channel	mRNA	transcripts	in	mouse	colonic	828 sensory	neurons	by	single-cell	qRT-PCR.	(A)	Proportions	of	thoracolumbar	and	829 lumbosacral	colonic	sensory	neurons	expressing	transcripts	for	NaV1.1,	NaV1.2,	NaV1.3,	830 NaV1.4,	NaV1.5,	NaV1.6,	NaV1.7,	NaV1.8	and	NaV1.9.	(B)	Relative	expression	of	NaV	831 transcripts	in	thoracolumbar	and	lumbosacral	colonic	sensory	neurones	(C)	Co-832 expression	analysis	of	voltage-gated	sodium	channels	in	both	thoracolumbar	and	833 lumbosacral	colonic	sensory	neuronal	populations.	Each	segment	in	the	wheel-diagrams	834 is	representative	of	a	single	cell	with	a	coloured	segment	signifying	positive	expression.		835 Figure	6	836 Somatic	pain	behaviors	and	tibial	nerve	activity	to	noxious	thermal	stimulation	in	837 NaV1.7Nav1.8	and	littermate	mice.	(A)	Thermal	pain	thresholds	in	NaV1.7Nav1.8	mice	are	838 significantly	increased	following	ramping	hotplate	behavioral	testing.	(B)	Average	839 thermal	pain	thresholds	following	the	application	of	selective	NaV1.7	antagonist	PF-840 
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5198007	(1	or	3mg/kg)	or	vehicle	in	NaV1.7Nav1.8	and	littermate	mice.	Example	raw	841 traces,	rate	histogram	and	temperature	recordings	of	tibial	nerve	activity	in	littermate	842 (C)	and	NaV1.7Nav1.8	mice	(D).	(E)	Sum	firing	of	tibial	nerve	activity	during	focal	heat	843 stimulation	in	skin-nerve	preparations	of	NaV1.7Nav1.8	and	littermate	mice	in	the	844 presence	of	TTX	(100nM)	or	vehicle	(0.1%	distilled	H2O).	####P	<	0.0001,	NaV1.7Nav1.8	845 baseline	vs.	littermate	baseline.	(F)	Effect	of	PF-5198007	on	evoked	tibial	nerve	firing	846 by	heat	stimulation	in	NaV1.7Nav1.8	and	littermate	mice.	(G)	Sum	firing	of	tibial	nerve	847 activity	during	focal	cold	stimulation	in	skin-nerve	preparations	of	NaV1.7Nav1.8	and	848 littermate	mice	in	the	presence	of	TTX	(100nM)	or	vehicle	(0.1%	distilled	H2O).	(H)	849 Effect	of	PF-5198007	on	evoked	tibial	nerve	firing	by	cold	stimulation	in	NaV1.7Nav1.8	850 and	littermate	mice.	*P	<	0.05,	**P	<	0.01,	****P	<	0.0001.	851 Figure	7	852 Effect	of	selective	small-molecule	antagonism	of	NaV1.7	in	resected	human	appendices	853 following	repeat	noxious	distension.	(A)	Example	rate	histogram	of	appendix	854 mesenteric	nerve	activity	and	intraluminal	pressure	trace	following	repeat	ramp	855 distension	(0-60	mm	Hg;	10	min	interval).	Application	of	PF-5198007	was	initiated	at	856 the	start	of	the	black	bar	and	maintained	for	50	min	during	which	distensions	were	857 continued.	(B)	Average	firing	rates	to	repeat	ramp	distension	(0-60	mm	Hg;	N	=	5)	of	858 human	appendix	prior	to,	and	after,	addition	of	PF-5198007;	neither	low-threshold	or	859 high-threshold	afferent	firing	is	affected	by	antagonism	of	NaV1.7.	Both	change	in	peak	860 firing	rate	(C)	and	total	afferent	firing	(D;	Area	Under	Curve)	were	unchanged	by	bath	861 superfusion	with	PF-5198007	(N	=	5).	862 
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# Disease Operation Tissue Age Sex 
1 Cancer Right hemicolectomy Appendix 83 F 
2 Cancer Right hemicolectomy Appendix 42 F 
3 Cancer Right hemicolectomy Appendix 72 F 
4 Slow Transit Constipation Subtotal Colectomy Appendix 69 M 
5 Cancer Right hemicolectomy Appendix 70 M 
   Mean age / M:F ratio 67 1:1.5 
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